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Center of Excellence for Poultry Science 
Faculty Mentor: Gisela Erf 
Associate Professor, Avian Immunology 
Abstract. 
The Arkansas Rous Sarcoma Regressor (AR) and 
Progressor (AP) lines of chickens represent an excellent model 
to study immune responses to tumors. Both lines of chickens 
initially develop tumors when injected with Rous sarcoma viros 
(RSV) or with DNA coding for the RSV oncogene v-src (v-src 
DNA). AR chickens will eventually regress the tumors whereas 
AP chickens will allow the tumors to progress to a terminal 
stage. By using both v-src DNA and RSV for tumor induction, we 
were able to compare the immune response to tumor antigens 
alone and tumor antigens in combination with vi raJ components, 
respectively. To study the ability ofv-src DNA to induce tumors 
in AR and AP chickens, 3-day-old AR and AP chicks were 
injected with v-src DNA, and the incidence and development of 
tumors was monitored. To gain insight into the role oflymphocytes 
in tumor regression, 9-week-old AR and AP chickens were 
injected into the wing web with either PBS (vehicle control), v-
src DNA in PBS, or RSV in PBS. Blood was collected prior to 
injection and during tumor development. Tumors were collected 
when present. Lymphocyte profiles in blood and tumors were 
determined by immunofluorescent staining with a panel of 
antibodies and flow cytometry. Based on tumor induction data, 
the level of the chicken's immunocompetence is important, not 
only in the ability to regress tumors, but also in the susceptibility 
to tumor induction by v-src DNA. Cell population analyses of 
tumor-infiltrating l)mphocytes (TIL) revealed the presence of 
different types and proportions of immune cells in DNA and RSV 
induced regressing and progressing tumors. DNA induced 
tumors were shown to display higher levels of regulatory T cells 
(CD4+) and a higher ratio ofCD4+ to CDS+ TIL than RSV 
induced tumors, indicating a different response occurs to tumor 
antigens alone versus tumor plus viral antigens. Additionally, 
the percentageofCD4+CD8+ TIL. a cell type usually not found 
in the periphery and whose function is unknown, was higher in 
AR tumors than AP tumors. Of particular interest was the 
discovery of CD8a-b+ TIL This cell type has been recently 
characterized using transgenic human cells, and appears to be 
an ineffective cytotoxic T cell subtype. The elevated proportions 
of this novel cell type in progressing tumors may contribute to the 
ineffective immune response in AP compared to AR birds. 
Brant Ward and Gisela Erf 
Introduction 
The immune system's response to tumor cells within the 
body involves a complex series of events that is difficult. at best. 
to explore and extrapolate. However, a system that allows for 
precise study of this phenomenon exists in the Arkansas Rous 
Sarcoma Regressor (AR) and Progressor (AP) lines of chickens. 
These two lines have been developed based on their characteristic 
immune responses to virus-induced tumors. When infected with 
Rous sarcoma virus (RSV), an acutely transforming avian 
retrovirus, both lines initially develop tumors at the site of 
infection. Several days later, birds of the ARline begin to show 
decreases in tumor mass, which eventually leads to the complete 
regression of the tumor. However, birds of the AP line allow the 
tumor to increase in size and to progress to a terminal stage. 
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These traits have been shown in other lines of chickens to be the 
result of an effective or non-effective immune response, 
respectively, in which the immune system is either able or unable 
to recognize and eradicate the tumor cells (Halpern eta/., 1993; 
Plachy et al., 1994; Taylor et al., 1994; Wisner et al., 1991). 
The drawback to this system is that when a virus is used to 
transform healthy cells into cancerous cells, the immune system 
"sees" two different types of antigens, or foreign proteins: those 
associated with the tumor itself and those associated with viral 
infection and replication. In order to overcome this and make 
sure that the immune response is directed only towards the 
cancer itself, one must transform cells without using a virus. It 
has been shown that DNA from the RSV gene v-src, which is 
responsible for causing the transformation of healthy cells into 
tumor cells, can itself cause tumors to develop in chickens 
(Halpern eta/., 1990; Halpern et al., 1991; Plachy et al., 1994; 
Taylor et al., 1994). Using v-src DNA to induce tumors allows 
for a direct investigation into the immune response against tumor 
cells. Therefore, it was the purpose of this project to examine the 
ability of v-src DNA to induce tumors in AR and AP chickens 
and to compare immune cell profiles in blood and tumors (if 
present) following v-src DNA or RSV injection into (9-week-
old) AR and AP chickens. 
Methods 
The RSV oncogene v-src was generously donated by Dr. 
Michael Halpern of the Medical College of Pennsylvania and 
Hahnemann University in the form of a bacterial plasmid, which 
was then cloned into a strain of E. coli by Dr. Mark Parcells of 
the University of Arkansas Department of Poultry Science. 
These bacteria were then grown in culture to amplify the amount 
of v-src. The plasmid containing the v-src gene was purified 
using a commercially available plasmid purification kit (Pro mega 
Corporation, Madison, WI). The purified plasmid DNA was 
examined by gel electrophoresis and compared to the known 
molecular weight of the original plasmid containing the v-src 
gene. To ensure proper expression in the chicken cells, the v-src 
gene had to be freed from the bacterial plasmid. This was 
accomplished by digestion with the restriction endonucleases 
EcoR I and Hind rn, which cut the plasmid at specific positions 
flanking the v-src gene (Halpern et al .• 1991 ). To prepare the cut 
DNA for injection into the chickens, it was precipitated in 
ethanol and then redissolved in phosphate buffered saline (PBS) 
to a final concentration of 1 mg/mL. 
A preliminary study was conducted to test the ability of v-
src DNA to induce tumors in AR and AP chickens. For this, 3-
day-old chicks from each line were injected into the wing web 
with v-src DNA in phosphate-buffered saline (PBS). Tumor 
development was monitored as outlined below. To study immune 
cell profiles in blood and tumors, 9-week-old AR and AP 
chickens were injected into the wing web with either PBS 
containing v-src DNA or RSV, or PBS alone (control). The birds 
were kept at the University of Arkansas Poultry Farm in floor 
pens and were observed for approximately seven weeks after 
injection. Every two or three days, the birds were examined and 
the sizes (0.1 mm) oftumors were recorded. For consistency, the 
largest axis of the tumor was always used for measuring purposes. 
All studies involving birds followed protocols in accordance 
with the Institutional Animal Care and Use. 
Blood samples were collected from the brachial vein of the 
9-week-old chickens before injection with experimental 
treatments and at ten days post-injection (tumor development 
phase). Once tumors were observed to be in a state of regression 
(AR, decreasing in size) or progression (AP, continually 
increasing in size), a blood sample was collected, the birds were 
euthanized and the tumors excised. On each tumor collection 
day, blood samples were also collected from chickens in the 
control group. Mononuclear blood cell suspensions were prepared 
by Ficoll density gradient centrifugation. Single cell suspensions 
from tumor tissues were prepared by mashing minced tumor 
tissue through a Nylon mesh (60 J.lm) into PBS. All cell 
suspensions were then stained with a panel of fluorescently-
labeled antibodies specific to particular proteins expressed on 
the surface of different immune cells as described by Erf et al. 
(1998). Cell-population analyses were then carried out by 1-, 2-
, and 3-color flow cytometry. Statistical analyses (ANOV A and 
multiple mean comparisons) were performed on the collected 
data. 
Results and Discussion 
Due to space limitations, only information from the tumors 
has been included in this section. Tumor incidence following 
injection with v-src or RSV differed between lines and between 
age groups. In the 3-day-old chicks, only 30% of the DNA-
injected AR chicks developed tumors, while 80% of the DNA-
injectedAP chicks developed tumors. In the 9-week -old chickens, 
tumors developed in 11% and 22% of v-src DNA-injected AR 
and AP chickens, respectively, whereas RSV injection caused 
tumors in all AR chickens and in 90% of AP chickens (Table 1 ). 
These data suggest that the level of immunocompetence of the 
chicken, which is positively related to age, is important in 
determining the sensitivity of AR, and especially, AP chickens 
to develop tumors in response to v-src DNA. Also, while the 
DNA induced tumors were visually and tactilely determined to 
consist of one large mass, the RSV induced tumors appeared to 
contain multiple small masses that eventually fused together, 
which may be indicative of the ways that the tumors develop (i.e., 
infection of new cells with virus, versus division of individual 
cells transformed with DNA) (Halpern et al., 1993). 
Analysis of immune cell populations in tumors from 9-
week-old birds by flow cytometry and subsequent statistical 
analysis led to several unique findings. All tumors contained 
considerable amounts of tumor-infiltrating lymphocytes (TIL). 
DNA induced tumors contained a higher percentage of regulatory 
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T helper cells (CD4+CD8-) than RSV induced tumors in both 
lines (Figure 1A). Surprisingly, the percentages of CD4-CD8+ 
TIL (generally considered cytotoxic T cells, which kill tumor 
and virus-infected cells) were not different in regressing and 
progressing tumors (Figure 1 B). Regressing tumors contained a 
higher percentage of CD4+CD8+ TIL than progressing tumors 
(Figure 1 C). CD4+CD8+ cells are a unique cell type not usually 
found in the periphery and whose function is not clearly 
understood. Our data suggest that these cells may serve an 
important role in the successful regression of a tumor. The 
proportions of CD4+ to CDS+ cells were higher in tumors from 
DNA injected birds than in RSV injected birds, suggesting an 
immunoregulatory difference in response to tumor antigens 
versus tumor plus viral antigens. Within the DNA treated birds, 
this ratio was also significantly different between AR and AP 
lines (Figure 2 ). In all tumors, there were more T cells expressing 
TCR2 (afi1 T cell receptor) than TCRl (yd T cell receptor) and 
TCR3 (aB2 T cell receptor). Within AP chickens, there were 
greater proportions of TCR1 + T cells in RSV induced tumors 
and a higher percentage of TCR2+ Tcells in DNA induced 
tumors. Within the RSV induced tumors, the percentage of 
TCR1 + T cells was higher in AP chickens, while AR birds had 
higher proportions of TCR2+ cells (Figure 3). These observed 
differences in the proportions ofTCR -defmed tumor infiltrating 
cells further suggest a difference in the types of cells responding 
to tumors in AR and AP chickens. Also of interest were the 
proportions of cells expressing the molecules CDSa and CDSB. 
AR birds injected with RSV displayed higher percentages of 
CDSa+B- TIL, a subset of functioning cytotoxic T cells, than AP 
birds (Figure 4A). DNA injected chickens displayed higher 
percentages of CDSa+B+ cells, another subset of functioning 
cytotoxic T cells, than did RSV injected birds (Figure 4B). Of 
special interest was the appearance of CDSa-B+ TIL within all 
types of tumor tissue (Figure 4C). While this cell type has not 
been defined in chickens, transgenic human cells expressing 
CDSBB homodimers have recently been shown to display 
ineffective cytotoxicity (Devine et al., 2000), which suggests 
that their heightened presence in AP chickens may contribute to 
the ineffective immune response to tumors in these birds. The 
proportions of CDSa-B+ TIL were higher in RSV induced 
tumors than in DNA induced tumors, and were higher in 
progressing tumors than in regressing tumors. 
Through this study, differences in the proportions among 
TIL have been identified in tumors of AR and AP chickens. 
These observations suggest that different immune mechanisms 
were initiated in both lines, further emphasizing the usefulness 
of this animal model for defining components of an effective 
anti-tumor/anti-virus immune response. The identification of 
unique cell-types, namely CD4+CD8+ and CD8a-B+ TIL, in 
tumors is a novel observation. Although these cells have not 
been fully characterized, their preferential association with 
regressing and progressing tumors, respectively, suggests an 
important role of these cells in the successful or unsuccessful 
regression of tumors. Future studies will attempt to ascertain the 
functions of these cell types. 
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Table 1: Dependence of Tumor Growth on Age and Chicken Line 
Inoculum 
v-src at 3 daysa 
v-src at 9 weeksa 
RSV at 9 weeksb 
Frequency of Chickens Developing Tumors 
Total 
11/20 (55%) 
6/36 (17%) 
20/22 (91%) 
Regressor 
3/10 (30%) 
2/13 (11%) 
11/11 (100%) 
Progressor 
8/10 (800;0) 
4/13 (22%) 
9/10(90%) 
a Eco R I- and Hind Ill-restricted plasmid DNA in PBS injected into the right wing web 
b 250 plaque-forming units RSV in PBS injected into the right wing web 
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Figure 1. Mean percentages ± SEM of tumor-infiltrating lymphocytes (TIL) 
expressing CD4 (A), CDS (B), or both CD4 and CDS (C) in DNA and RSV 
induced tumors in AR and AP chickens. T-wo-color flow cytometric analyses of 
tumor cells were carried out using FITC-labeled mouse anti-chicken CD4 
monoclonal antibodies (mAb) and PE-labeled mouse anti-chicken CDS mAb. 
Numbers shu-w71 are percentages of total TIL, which were determined by jlu-.JJ 
cytometric analysis using mouse anti-chicken K55 mAb (specific to lympho-
cytes). Within a line, means u:ith d~fjerent letters (a, b) are significantly dWerent 
(P < 0.05). Di_fjerences (P < 0.05) bet-.JJeen lines but within treatments are 
indicated with an asterisk. 
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Figure 2. Ratios (mean ± SEM) of tumor-infiltrating lymphocytes (TIL) 
expressing only CD4 to those expressing only CDS in DNA and RSV induced 
tumors in AR and AP chickens. Ratios were calculated jron1 two-color jlu-.JJ 
cytometric analyses of tumor cells using FITC-labeled mouse anti-chicken CD4 
monoclonal antibodies (mAb) and PE-labeled mouse anti-chicken CDS mAb. 
Within a line, means with dWerent letters (a, b) are significantly different (P < 
0.05). DWerences (P < 0.05) bet-.JJeen lines but within treatments are indicated 
with an asterisk. 
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Figure 3. Mean percentages ±SEM oftumor-infiltrating(Tl) T cells expressing 
TCRl(A),TCR2(B),orTCR3(C)inDNAandRSVinducedtumorsinARand 
AP chickens. Single-color flo-.c cytometric analyses of tumor cells were carried 
out using biotin-labeled mouse anti-chicken TCRl, TCR2, or TCR3 monoclonal 
antibodies (mAb ). Binding of the biotinylated mAb was detected by quantum-
red-labeled strepavidin. Numbers shOUJn are percentages of total TI cells 
expressing aT cell receptor (TCRl + TCR2+ TCR3). Within a line, means v.Jith 
different letters (a, b) are significantly different (P < 0.05). Differences (P < 0.05) 
betv.Jeen lines but within treatments are indicated v.Jith an asterisk. 
100 
A I - Regressor 
eo az==a Progressor 
-l 
i= 
' 60 = + Ji 
* 0 40 (..) 
fl. 
20 
0 DNA RSV 
100 
B 
80 
-l 
i= 
+ 60 
= l 
0 40 
0 
';F. 
20 
0 DNA RSV 
100 
* c 
eo a 
-l 
i= 
+ 60 cr 
,B 
0 40 0 
';F. 
20 
0 DNA RSV 
Treatment 
Figure 4. Mean percentages ± SEM of tumor-infiltrating lymphocytes (TIL) 
expressing CD Sa (A), both CDSa and CDS}J (B), or only CDS}J (C) in DNA and 
RSV induced tumors in AR and AP chickens. Two-color flcr.c cytometric 
analyses of tumor cells were carried out using FITC-Iabeled mouse anti-chicken 
CDS}J monoclonal antibodies (mAb) and PE-Iabeled mouse anti-chicken CDSa 
mAb. Numbers shOUJn are percentages of total TIL, which were determined by 
flo-.c cytometric analysis using mouse anti..::hicken K55 mAb (specific to lympho-
cytes). Within a line, means v.Jith different letters (a, b) are significantly different 
(P < 0.05). Differences (P < 0.05) bet-.ceen lines but within treatments are 
indicated v.Jith an asterisk. 
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Faculty Comments: 
Mr. Ward's mentor, Gisela Erf, Associate Professor of 
Avian Immunology, writes about his research as follows: 
I am writing this letter in support of the research 
paper submitted by Brant Ward for publication in the 
University of Arkansas Journal of Undergraduate 
Research. Brant has worked diligently on every aspect 
ofthis project from the design of the experiment, 
preparation of V -src DNA, sample processing and 
data collection, data analysis, literature research, to 
writingofthepaper.NotonlyhasBrantdemonstrated 
excellent technical skills and comprehension ofthe 
subject matter, he also demonstrated an excellent 
ability to condense one aspect of his research into this 
fivepagemanuscript.lhisisparticularlynoteworthy, 
as Brant collected a tremendous amount of data that 
were diff' cult to interpret due to the novel approach 
used (no comparable published data were available) 
and to the unique discoveries, such as previously 
undefined avian cell types (e.g., CD8a-JS+ cells), 
present in the tumors. His findings will form the 
foundation for continued research in this area. 
The immune system is a tightly regulated system 
orchestrating the function of many types of immune 
cellsindefendingthebodyfromdisease. Theimmune 
system has developed defined approaches to deal 
with a variety of challenges, such as infection by 
bacteria, viruses, or parasites, and the development 
oftumors. In chickens we are in the process of trying 
to understand the immune mechanisms required to 
effectively respond to viral infection and tumor cells. 
With the development and availability of cell-specific 
markers (e.g., the monoclonal antibodies used here) 
andstate-of-the-arttechnology(e.g.,flowcytometry), 
we have been able to examine and identify cells 
involved in various types of immune responses in 
chickens. The animal model used here (AR and AP 
lines of chickens) pro·vides an excellent opportunity 
to study responses to viruses or tumor antigens that 
arepredictablysuccessful or unsuccessful. Knowledge 
of the mechanisms initiated in a successful response 
to virus and/ or tumor antigens will find direct 
application in vaccine development, and hence 
improvedhealth of avian species. Moreover, the ability 
toexaminedevelopingtumorsinARandAPchickens 
provides insight into events that lead to the natural 
regression and elimination ofthe cancer tissue. 
Although there are lines of chicken similar to AR and 
AP lines, the type of studies described in Brant's 
paper has only been conducted in our laboratory 
(manuscripts in preparation). Brant' sprojecthasadded 
a new dimension to our research efforts in that v-src 
DNA was used as a tumor inducing agent, resulting 
in tumors in the absence of a virus challenge. Although, 
the incidence of tumors in the AR line of chickens, 
known to mount an effective immune response against 
tumors, was low when v-src was used, this finding in 
itself is novel and will open a new venue of studying 
aspects of tumor prevention and elimination. The 
discovery of previously undefined cell-types in the 
avian system will lead to further studies on the 
mechanisms leading their development, their 
localization in tumor tissues, and their role in tumor 
regression. Brant's contributions to our research efforts 
and those within the field of avian immunology are 
highly significant. 
Nick B. Anthony, Professor of Poultry Genetics, writes 
about Mr. Ward's research: 
I consider Brant Ward's work to be an outstanding 
contribution to our understanding of poultry 
immunology and tumor immunology. 
Brant is conducting his Honors research project under 
the guidance of Dr. Gisela Erf who is my colleague 
and collaborator in the Department ofPoultryScience. 
I am a poultry geneticist and have been maintaining 
the Arkansas Rous Sarcoma Regressor (AR) and 
Progressor (AP) lines of chickens since the retirement 
of Dr. Roy Gyles who originally developed these 
lines. When injected with Rous sarcoma virus (RSV) 
into the wing web, these lines of chickens develop 
tumors at the site of infection. The unique 
distinguishing feature between chickens from the AR 
and AP lines is, however, the ability of AR chickens to 
eliminate the tumor whereas AP chickens allow the 
tumor to grow. The importance and acceptance of 
these lines of chickens as animal models for the study 
of cell-mediated immunity and tumor immunology is 
demonstrated by the award of a grant from the USDA 
(Erf, PI) in support of this research area. 
The studies conducted by Brant confirm the hypothesis 
that different immune mechanisms are called into 
action in animals able to regress tumors compared to 
those allowing the tumor to progress. Additionally, 
the fact that Brant was able to induce tumors with 
viral DNA (v-src) rather than the whole virus (RSV), 
revealed that different types and amounts of immune 
cells respond to tumor antigens (v-src-induced tumors) 
compared to tumor and viral antigens (RSV-induced 
tumors). Lastly, the observation of a new cell-type 
present in tumors (especially progressing tumors) of 
these chickens is a unique and important discovery. 
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